Lung cancer remains the leading cause of cancer-related death worldwide. Epidermal growth factor receptor (EGFR) mutations are among the most common oncogenic drivers in non-small cell lung cancer (NSCLC), with L858R point mutation or exon 19 deletions accounting for the majority of EGFR mutations. The development of EGFR-targeted therapies has significantly improved clinical outcomes and overall survival in patients harboring these classical activating mutations. However, EGFR exon 20 insertion mutations (Ex20ins) exhibit resistance to earlier-generation tyrosine kinase inhibitors (TKIs), including erlotinib, gefitinib, and afatinib, due to structural alterations that limit drug binding and reduce therapeutic efficacy. To address these challenges, novel EGFR-targeted TKIs and bispecific monoclonal antibodies have emerged as promising treatment strategies for patients with Ex20ins-mutated NSCLC. This review summarizes recent advances in targeted therapies for EGFR Ex20ins, highlighting treatments approved by the US Food and Drug Administration (FDA), including amivantamab and sunvozertinib, as well as emerging agents such as firmonertinib, zipalertinib, and becotarug.
Background and Objective: Small cell lung cancer (SCLC) has long represented an area of slow progress in oncology, marred by a history of innumerable failed trials and poor outcomes. Immunotherapy subsequently emerged as a promising player in SCLC, propelled into the proverbial spotlight by positive results from the IMpower133 and CASPIAN trials, examining combined chemotherapy and immunotherapy in extensive stage SCLC (ES-SCLC). Although immunotherapy’s role in limited stage SCLC (LS-SCLC) was not well defined, the ADRIATIC trial is an impressive leap forward in the treatment of LS-SCLC, establishing consolidative immunotherapy’s utility following induction chemoradiation. Here, we provide an overview of failed maintenance trials in LS-SCLC and propose explanations for the ADRIATIC trial’s success following numerous failed trials. Methods: We searched for relevant trials via PubMed, ClinicalTrials.gov, and major scientific proceedings, including the European Society for Medical Oncology (ESMO), the American Society of Clinical Oncology (ASCO), and the World Conference on Lung Cancer (WCLC). Our search included immunotherapy trials in LS-SCLC and ES-SCLC, as well as those examining immunotherapy and other novel therapies as maintenance therapy in LS-SCLC. The trials identified spanned June 1986 to May 2025. Abstracts and publications in English were eligible. Key Content and Findings: Our search yielded 31 relevant studies. The IMpower133 and CASPIAN trials first demonstrated immunotherapy’s role in the frontline treatment of ES-SCLC. These results were mirrored in the CAPSTONE-1 and ASTRUM-005 trials. The CheckMate 451 (ES-SCLC) and STIMULI (LS-SCLC) trials, which examined maintenance immunotherapy, failed to show benefit. Other trials examining other novel therapies as maintenance therapy in SCLC also failed to show benefit. The ADRIATIC trial was the first to demonstrate benefit with maintenance immunotherapy following concurrent chemoradiotherapy (cCRT) in LS-SCLC. Conclusions: The ADRIATIC trial demonstrated immunotherapy’s utility as maintenance therapy following cCRT in LS-SCLC and established durvalumab consolidation as the standard of care in this space. The trial’s positive results raise questions regarding the mechanisms underlying its success, particularly in light of negative results from earlier trials. Future studies exploring the utility of other novel therapies, combination approaches, and sequences of therapy in LS-SCLC are needed.